Ori Biotech and Germfree to collaborate in modular facility integration, automation and scale out for cell and gene manufacturing

Philadelphia, PA and Ormond Beach, FL – June 15, 2020 – Ori Biotech Ltd (Ori), an innovator in cell and gene therapy (CGT) manufacturing, and Germfree Laboratories Inc (Germfree), experts in providing process-ready, mobile and modular cleanrooms for CGT manufacturing today announced a collaboration partnership to create an intensified, manufacturing platform that will facilitate higher throughput in both centralized and decentralized CGT manufacturing models.

“Ori Biotech continues to build partnerships with best-in-class expert suppliers across the cell and gene therapy ecosystem, like Germfree, to help enable our vision for a fully integrated, closed system manufacturing platform supporting the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “Innovation that reduces the significant size and cost of cell and gene therapy manufacturing facilities is another step toward enabling our customers to bring their life saving treatments to patients at scale.”

“Germfree has a long history of developing cleanroom technologies for specific applications based on tractor trailer and modular building platforms,” said Kevin Kyle, President, Germfree. “We are excited to be partnering with a ground-breaking company like Ori Biotech to deliver the vision of vein-to-vein point of care for personalized medicine delivery.”

“With cost of building bricks and mortar manufacturing facilities reaching $50M-$100M, an Ori powered Germfree mobile or modular manufacturing unit could provide the capability to manufacture thousands of doses of an individual advanced therapy in a much smaller footprint which could reduce the upfront investment required by up to 75%” added Jason C. Foster, CEO, Ori Biotech.

About Germfree

Germfree creates environments that serve life science innovation and advance global health. Germfree designs and manufactures flexible cGMP-compliant cleanroom buildings and high-containment facilities which are process or containment-ready upon deployment. Our facilities are designed to integrate with Germfree’s core equipment including our lines of interchangeable laminar flow hoods and containment equipment. Established in 1962 Germfree’s leading-edge fabrication technology, engineering teams and subject-matter experts are located at our 173,000 square foot (16,000 square meter) US manufacturing plant. Visit our website www.germfree.com for more information or contact us at media@germfree.com.

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine, Anthony Davies and Annalisa Jenkins.

For more information contact:

Germfree
Four Sunshine Blvd
Ormond Beach
Florida 32174, USA
Tel: +1 386-265-4360
Contact Email: media@germfree.com

Ori Biotech
Jason C. Foster
CEO
jasonfoster@oribiotech.com

info@oribiotech.com

Oribiotech Ltd
London Biosciences Innovation Centre
2 Royal College Street
London
NW1 0NH